
Loading, please wait...

Loading, please wait...

Researchers recently conducted a prospective randomized study to evaluate the SR2000 robotic surgical system against the industry-standard Da Vinci Xi. The study focused on patients undergoing robot-assisted partial nephrectomy (RAPN). Consequently, the results provide critical insights for urologists considering domestic robotic platforms as viable alternatives to established systems.
The analysis included 90 patients randomized between the two surgical systems. Notably, the researchers found no significant differences in docking time, operative time, length of hospital stay, or intraoperative blood loss. All 90 procedures were completed successfully without converting to open or traditional laparoscopic surgery. Additionally, every patient achieved negative surgical margins, ensuring high standards of oncological safety.
One of the most significant findings involves the transition process for experienced robotic surgeons. While many doctors already use the Da Vinci Xi, switching to a new platform often requires specific technical adjustments. The study suggests that Da Vinci-proficient surgeons need about 18 cases to master the SR2000 robotic surgical system.
Furthermore, the domestic group recorded a 23-minute warm ischemia time versus 24 minutes in the Da Vinci group. Although this difference was not statistically significant, it demonstrates that the domestic robot performs reliably during the most critical phases of nephron-sparing surgery. Therefore, the SR2000 appears both safe and effective for complex renal procedures. Its comparable performance metrics suggest it could play a major role in expanding access to robotic urological care.
For surgeons already experienced with the Da Vinci Xi platform, this study indicates that technical proficiency with the SR2000 system is typically achieved after approximately 18 cases.
Yes, the clinical trial showed that both systems had comparable safety profiles. There were no statistically significant differences in blood loss, complication rates, or the achievement of negative surgical margins.
The SR2000 group had a mean warm ischemia time of 23 minutes, compared to 24 minutes in the Da Vinci Xi group. However, researchers noted that this slight difference was not statistically significant (p > 0.05).
Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.
References
Li JQ et al. [A comparative study on perioperative outcomes and learning curves of domestic robot-assisted versus Da Vinci Xi robot-assisted partial nephrectomy]. Zhonghua Wai Ke Za Zhi. 2026 Mar 25. doi: 10.3760/cma.j.cn112139-20250801-00386. PMID: 41881798.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A study comparing the China-made SR2000 robotic system and Da Vinci Xi for partial nephrectomy found similar safety, efficacy, and an 18-case learning curve...
6 months ago

As monsoon seasons elevate arboviral disease threats, Tamil Nadu has initiated an ICMR-monitored evaluation of the tetravalent dengue vaccine in Tenkasi district. Clinicians emphasize clinical monitoring, public prevention, and high-quality early pediatric care to reduce disease morbidity across endemic regions.
Today

Leucine Rich Bio has introduced South Asia's first comprehensive vaginal microbiome test, BugSpeaks. By profiling microbial dysbiosis, pathogens, and antimicrobial resistance, this next-generation diagnostic platform provides clinicians with deeper insights into recurrent infections, fertility, and reproductive health.
Today

Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Today

This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Today

A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today